- Home
- CPT vs QGEN Comparison
CPT vs QGEN Comparison
Compare CPT & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | QGEN |
|---|---|---|
| Founded | 1993 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.2B |
| IPO Year | 1993 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CPT | QGEN |
|---|---|---|
| Price | $104.01 | $45.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 7 |
| Target Price | ★ $119.78 | $49.74 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.03% | 3.34% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | ★ 2.47 | 1.84 |
| Revenue | $1,578,428,000.00 | ★ $2,070,781,000.00 |
| Revenue This Year | $2.48 | $7.12 |
| Revenue Next Year | $1.94 | $6.13 |
| P/E Ratio | $42.16 | ★ $24.59 |
| Revenue Growth | 1.41 | ★ 5.32 |
| 52 Week Low | $97.17 | $37.63 |
| 52 Week High | $126.55 | $51.88 |
Technical Indicators
Market Signals| Indicator | CPT | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 42.22 |
| Support Level | $101.59 | $45.55 |
| Resistance Level | $106.77 | $47.48 |
| Average True Range (ATR) | 1.57 | 0.59 |
| MACD | -0.18 | -0.17 |
| Stochastic Oscillator | 44.86 | 11.63 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).